Frontotemporal dementia (FTD) is one of the harder dementias to diagnose, largely because it strikes earlier than most people expect and its symptoms often look like psychiatric conditions. About 60% of people with FTD are between 45 and 64 years old, and many are initially told they have depression, bipolar disorder, or obsessive-compulsive disorder before the real cause is identified. Diagnosis relies on a combination of behavioral and cognitive evaluation, brain imaging, and sometimes genetic testing, with no single test that confirms it on its own.
Why FTD Is So Often Misdiagnosed
FTD is frequently confused with Alzheimer’s disease, psychiatric disorders, vascular dementia, or Parkinson’s disease. The reason comes down to what FTD looks like from the outside. When behavioral symptoms dominate, a middle-aged person might appear to have late-life depression. In younger patients, the changes can resemble schizophrenia or bipolar disorder. Repetitive, compulsive behaviors are extremely common in the behavioral variant of FTD, and some patients initially receive a diagnosis of obsessive-compulsive disorder.
This matters because the path to a correct diagnosis often takes years. FTD doesn’t typically start with the memory loss people associate with dementia. Instead, families notice personality changes, loss of social awareness, or difficulty with language. These shifts can be subtle at first and easy to attribute to stress, midlife changes, or mental health conditions.
The Two Main Types of FTD
FTD isn’t a single disease. It falls into two broad categories, and the diagnostic approach differs depending on which symptoms appear first.
Behavioral variant FTD (bvFTD) is the most common form. Clinicians look for six core symptoms: behavioral disinhibition (saying or doing inappropriate things), apathy or inertia, loss of sympathy or empathy, repetitive or compulsive behaviors, hyperorality (overeating, dietary changes, or putting objects in the mouth), and a specific pattern on cognitive testing that shows problems with executive function while memory stays relatively intact. A person needs to show at least three of these six features for a clinical diagnosis to be considered.
Primary progressive aphasia (PPA) covers the language-dominant forms of FTD. There are three recognized variants. The agrammatic variant produces speech that is effortful and grammatically broken, sometimes with difficulty coordinating mouth movements for speech. The semantic variant causes a progressive loss of word meaning: a person might not recognize what common words refer to, even though their speech remains fluent. The logopenic variant involves trouble finding words and difficulty repeating sentences, but word knowledge itself stays intact. Each of these has a distinct pattern on brain imaging, which helps confirm the subtype.
Behavioral and Cognitive Evaluation
The diagnostic process usually begins with a detailed clinical interview, often involving both the patient and a family member or close friend. Because people with bvFTD frequently lack insight into their own behavioral changes, input from someone who knows them well is essential. Clinicians use structured scales like the Cambridge Behavioral Inventory and the Neuropsychiatric Inventory to quantify changes in behavior, personality, and daily functioning.
Cognitive testing in FTD goes beyond standard memory screening. The Addenbrooke’s Cognitive Examination (now in its third edition) provides a score out of 100 with sub-scores across multiple domains, giving clinicians a detailed profile of where cognition is breaking down. For FTD specifically, tests that measure social cognition and emotional processing are particularly useful. Tools like the Social Cognition and Emotional Assessment, the Faux Pas Test, and the Awareness of Social Inference Test help detect the kind of social blindness that is characteristic of bvFTD but absent in Alzheimer’s.
For language variants, specialized batteries include tasks like word reading, semantic matching, sentence repetition, and anagram solving. The pattern of which language tasks a person fails helps distinguish among the three PPA subtypes. A person with the semantic variant, for example, will struggle to match words with their meanings, while someone with the agrammatic variant will have trouble constructing grammatically correct sentences.
Brain Imaging
Structural MRI is one of the most important tools in diagnosing FTD because each subtype produces a recognizable pattern of brain shrinkage. In behavioral variant FTD, the frontal and temporal lobes lose significant gray matter volume, with the earliest and most distinctive loss appearing in the insula and anterior cingulate cortex, regions that help regulate social behavior, motivation, and emotional awareness.
The PPA variants show even more distinctive patterns. Semantic variant PPA produces striking, asymmetric atrophy of the temporal pole, typically worse on the left side. Agrammatic variant PPA shows atrophy concentrated in the left inferior frontal and insular cortex, the areas most involved in speech production and grammar. These patterns can be visible on a standard MRI, though specialized volumetric analysis makes them easier to detect in early stages.
FDG-PET scanning, which measures how actively different brain regions are using glucose, adds another layer. In FTD, the frontal and anterior temporal lobes show reduced metabolic activity. One consistent finding is that this reduced activity is almost always asymmetric, appearing more prominently in one hemisphere. About 90% of FTD patients in one study showed this hemispheric asymmetry. This pattern helps distinguish FTD from Alzheimer’s disease, where reduced metabolism tends to center on the posterior parts of the brain instead.
Blood-Based and Spinal Fluid Biomarkers
There is no blood test that definitively confirms FTD, but emerging biomarkers are improving the diagnostic process. One of the most promising is a protein called neurofilament light chain (NfL), which leaks into the blood when nerve cells are damaged. In people with symptomatic FTD caused by known genetic mutations, plasma NfL levels average around 50 pg/mL, compared to roughly 9 pg/mL in healthy individuals. At a cutoff of about 19.8 pg/mL, this blood test correctly identified symptomatic patients about 87% of the time and correctly ruled out presymptomatic individuals about 84% of the time.
NfL isn’t specific to FTD. It rises in many neurodegenerative diseases. But it’s useful for distinguishing active neurodegeneration from psychiatric conditions, which is one of the biggest diagnostic hurdles in FTD. If someone presents with behavioral changes and their NfL levels are elevated, that points toward a neurodegenerative process rather than a primary psychiatric disorder. Spinal fluid testing can also help rule out Alzheimer’s by checking for the protein patterns (amyloid and tau) that characterize that disease instead.
Genetic Testing
FTD has a stronger genetic component than most other dementias. Roughly 10 to 20% of cases are caused by mutations in one of three genes: C9orf72, MAPT, or GRN. A family history of dementia, motor neuron disease, or psychiatric illness in a first-degree relative raises the likelihood of a genetic cause. Genetic testing is typically offered when there is a clear family history or when the person is unusually young at symptom onset.
Each genetic mutation tends to produce somewhat different clinical features and brain imaging patterns, so identifying the specific gene involved can help predict the disease course. Genetic counseling is a standard part of this process, since a positive result has implications for biological relatives who may carry the same mutation.
How the Pieces Come Together
No single test confirms FTD. Diagnosis works by layering evidence: clinical symptoms match a recognized pattern, cognitive testing reveals deficits consistent with frontal or temporal lobe dysfunction, brain imaging shows atrophy or reduced metabolism in the expected regions, and other causes (like Alzheimer’s or treatable psychiatric conditions) have been ruled out. When the clinical picture and imaging align, clinicians move from a “possible” to a “probable” diagnosis. A definitive diagnosis, technically, can only be confirmed by examining brain tissue after death, though in practice a probable diagnosis from a specialized center is highly reliable.
If you suspect FTD in yourself or a family member, the most effective step is getting a referral to a behavioral neurology or memory disorders clinic with specific experience in frontotemporal dementia. General neurologists and primary care physicians are less likely to recognize the condition early, particularly when memory appears intact and the primary changes are behavioral. Specialized centers have access to the full range of cognitive assessments, imaging protocols, and genetic testing needed to reach an accurate diagnosis.